@article{JTD9305,
author = {William B. Hillegass and Gregory S. Bradford},
title = {Risk guided use of the direct thrombin inhibitor bivalirudin: insights from recent trials and analyses},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {9},
year = {2016},
keywords = {},
abstract = {During percutaneous coronary intervention, dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist are combined with one of three major strategies for antithrombotic therapy: heparins, bivalirudin, or heparin with an intravenous IIb/IIIa platelet receptor antagonist. Economic constraints in the United States are increasingly driving the choice between these therapies.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/9305}
}